Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence

Launched by UNIVERSITY OF ARKANSAS · Jul 17, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment called Candin for patients with a type of throat and neck cancer known as squamous cell carcinoma. The goal is to see if Candin can help prevent the cancer from coming back after patients have finished their initial treatment, like surgery or radiation. In this study, some participants will receive Candin, while others will receive a placebo (which looks like the treatment but has no active ingredients) to compare the results. The study will involve about 68 participants, and they will be monitored over two years.

To join the trial, participants need to be at least 18 years old and have recently completed their cancer treatment, showing no signs of disease. Women who are pregnant or breastfeeding, or who might become pregnant during the study, cannot participate. If you decide to join, you will receive either Candin or the placebo, and your health will be closely monitored throughout the study to ensure your safety and to track how well the treatment works. This trial is currently looking for volunteers, so if you think you might be eligible, it could be a worthwhile opportunity to help advance cancer treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Able to provide informed consent
• • Male or female 18 years of age or older
• • Squamous cell carcinoma of the head and neck who have completed curative therapy (surgery and/or radiation and/or chemotherapy) within the previous 120 days.
• • No Evidence of Disease (NED) based on clinical and/or radiographic evaluations
• • Willing and able to comply with the requirements of the protocol
• Exclusion Criteria:
• • Positive urine pregnancy test for women of childbearing potential
• • Being pregnant or attempting to be pregnant with the period of study participation
• • Women who are breast feeding or plan to breast feed within the period of study participation
• • Patients who are allergic to Candin®
• • If in the opinion of the PIs or other Investigators, it is not in the best interest of the patient to enter or continue in this study